It’s at least a little ghoulish to read the reports of
the coronavirus outbreak in China and think “how can I profit from
this?”, but the reality is that outbreaks like these can be stock
drivers. While I think the financial impact to GenMark Diagnostics (GNMK) will be limited, it may drive more investor attention toward the stock and shrink some of the valuation gap I see.
The
big challenge for GenMark remains driving sales and profitability of
its core ePlex offering. A limited testing menu is definitely a
challenge to adoption, and management has not been producing the sort of
beat-and-raise guidance you’d like to see, but the Street is not
factoring in much chance at of long-term success.
Read more here:
Coronavirus May Drive Extra Attention Toward GenMark, But Adoption Trends Are Critical
No comments:
Post a Comment